The Epigenetic Evolution of Glioma Is Determined by the IDH1 Mutation Status and Treatment Regimen.

Autor: Malta TM; School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil., Sabedot TS; Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan., Morosini NS; Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan., Datta I; Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan., Garofano L; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Vallentgoed W; Neurology Department, The Brain Tumour Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Varn FS; The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut., Aldape K; National Cancer Institute, Bethesda, Maryland., D'Angelo F; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.; Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, Florida., Bakas S; Center for Biomedical Image Computing and Analytics, University of Pennsylvania, Philadelphia, Pennsylvania.; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.; Department of Radiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania., Barnholtz-Sloan JS; National Cancer Institute, Bethesda, Maryland., Gan HK; Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Melbourne, Australia., Hasanain M; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Hau AC; Luxembourg Institute of Health, Luxembourg, Luxembourg., Johnson KC; Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut., Cazacu S; Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan., deCarvalho AC; Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan., Khasraw M; Duke University, Durham, North Carolina., Kocakavuk E; Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut.; Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), National Center for Tumor Diseases (NCT) West, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Kouwenhoven MCM; Department of Neurology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Migliozzi S; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida., Niclou SP; Luxembourg Institute of Health, Luxembourg, Luxembourg., Niers JM; Department of Neurology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Ormond DR; University of Colorado School of Medicine, Department of Neurosurgery, Aurora, Colorado., Paek SH; Department of Neurosurgery, Cancer Research Institute, Hypoxia Ischemia Disease Institute, Seoul National University, Seoul, Republic of Korea (South)., Reifenberger G; Institute of Neuropathology, Heinrich Heine University, Dusseldorf, Germany., Sillevis Smitt PA; Department of Neurology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; The Brain Tumour Centre, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Smits M; Department of Radiology and Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands., Stead LF; Leeds Institute of Medical Research, University of Leeds, Leeds, United Kingdom., van den Bent MJ; Department of Neurology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; The Brain Tumour Centre, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Van Meir EG; Department of Neurosurgery and O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama., Walenkamp A; University of Groningen, Groningen, the Netherlands., Weiss T; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland., Weller M; Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland., Westerman BA; Department of Neurology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Ylstra B; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Wesseling P; Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; Brain Tumor Center Amsterdam, Cancer Center Amsterdam, Amsterdam UMC, VU University Medical Center, Amsterdam, the Netherlands.; Laboratory for Childhood Cancer Pathology, Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Lasorella A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.; Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, Florida., French PJ; Neurology Department, The Brain Tumour Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Poisson LM; Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan., Verhaak RGW; Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut.; Department of Neurosurgery, Amsterdam University Medical Center, Amsterdam, the Netherlands., Iavarone A; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida.; Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, Florida., Noushmehr H; Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, Michigan.

Publikováno v: Cancer research [Cancer Res] 2024 Mar 04; Vol. 84 (5), pp. 741-756.

Hemizygous CDKN2A deletion confers worse survival outcomes in IDHmut-noncodel gliomas.

Autor: Kocakavuk E; Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA.; Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), National Center for Tumor Diseases (NCT) West, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Johnson KC; Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA., Sabedot TS; Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, Michigan, USA., Reinhardt HC; Department of Hematology and Stem Cell Transplantation, West German Cancer Center (WTZ), National Center for Tumor Diseases (NCT) West, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Noushmehr H; Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, Michigan, USA., Verhaak RGW; Department of Neurosurgery, Yale School of Medicine, New Haven, Connecticut, USA.; Department of Neurosurgery, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Publikováno v: Neuro-oncology [Neuro Oncol] 2023 Sep 05; Vol. 25 (9), pp. 1721-1723.

Glioma progression is shaped by genetic evolution and microenvironment interactions.

Autor: Varn FS; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA., Johnson KC; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA., Martinek J; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA., Huse JT; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nasrallah MP; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA., Wesseling P; Amsterdam University Medical Centers/VUmc, Amsterdam, the Netherlands; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Cooper LAD; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Malta TM; School of Pharmaceutical Sciences of Ribeirao Preto, University of São Paulo, Brazil, Ribeirao Preto, São Paulo, Brazil., Wade TE; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA., Sabedot TS; Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI, USA., Brat D; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Gould PV; service d'anatomopathologie, Hôpital de l'Enfant-Jésus du Centre hospitalier universitaire de Québec, Université Laval, Quebec City, QC, Canada., Wöehrer A; Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria., Aldape K; National Cancer Institute, Bethesda, MD, USA., Ismail A; Department of Cellular and Molecular Pathology, Leeds Teaching Hospital NHS Trust, St James's University Hospital, Leeds, UK., Sivajothi SK; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA., Barthel FP; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Cancer and Cell Biology Division, the Translational Genomics Research Institute, Phoenix, AZ, USA., Kim H; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Department of Biopharmaceutical Convergence, Department of Pharmacy, Sungkyunkwan University, Suwon-si, Gyeong gi-do, South Korea., Kocakavuk E; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, Essen, Germany., Ahmed N; University of Leeds, Leeds, UK., White K; Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland., Datta I; Department of Public Health Sciences, Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI, USA., Moon HE; Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea., Pollock S; University of Leeds, Leeds, UK., Goldfarb C; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA., Lee GH; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA., Garofano L; Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA., Anderson KJ; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA., Nehar-Belaid D; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA., Barnholtz-Sloan JS; Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, OH, USA; Center for Biomedical Informatics and Information Technology & Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA., Bakas S; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA., Byrne AT; Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, D02 YN77 Dublin, Ireland., D'Angelo F; Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA., Gan HK; Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, Australia., Khasraw M; Preston Robert Tisch Brain Tumor Center at Duke, Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA., Migliozzi S; Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA., Ormond DR; Department of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA., Paek SH; Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Republic of Korea., Van Meir EG; Department of Neurosurgery, School of Medicine and O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA., Walenkamp AME; Department of Medical Oncology, University Medical Center Groningen, Groningen, the Netherlands., Watts C; Academic Department of Neurosurgery, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Weiss T; Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zürich, Switzerland., Weller M; Department of Neurology, Clinical Neuroscience Center, University Hospital Zurich and University of Zürich, Switzerland., Palucka K; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA., Stead LF; University of Leeds, Leeds, UK., Poisson LM; Department of Public Health Sciences, Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI, USA., Noushmehr H; Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI, USA., Iavarone A; Institute for Cancer Genetics, Columbia University Medical Center, New York, NY, USA; Department of Neurology, Columbia University Medical Center, New York, NY, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY, USA; Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA., Verhaak RGW; The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA; Department of Neurosurgery, Amsterdam University Medical Centers/VUmc, Amsterdam, the Netherlands. Electronic address: roel.verhaak@jax.org.

Publikováno v: Cell [Cell] 2022 Jun 09; Vol. 185 (12), pp. 2184-2199.e16. Date of Electronic Publication: 2022 May 31.

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma.

Autor: Tesileanu CMS; Neurology Department, Erasmus MC, Rotterdam, the Netherlands., van den Bent MJ; Neurology Department, Erasmus MC, Rotterdam, the Netherlands., Sanson M; Sorbonne Université, Hôpitaux Universitaires La Pitié Salpêtrière, Paris, France., Wick W; Neurology Department, Universitätsklinikum Heidelberg, Heidelberg, Germany., Brandes AA; Medical Oncology Department, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy., Clement PM; Oncology Department, KU Leuven and Medical Oncology Department, UZ Leuven, Leuven, Belgium., Erridge SC; Neuro-Oncology Centre Edinburgh, Western General Hospital, Edinburgh, UK., Vogelbaum MA; Neuro-Oncology Department, Moffitt Cancer Center, Tampa, Florida, USA., Nowak AK; University of Western Australia, Perth, Australia.; Co-Operative Group for Neuro-Oncology, University of Sydney, Sydney, Australia.; Medical Oncology Department, Sir Charles Gairdner Hospital, Nedlands, Australia., Baurain JF; Medical Oncology Department, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Brussels, Belgium., Mason WP; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Wheeler H; Northern Sydney Cancer Centre, Sydney, Australia., Chinot OL; Neuro-Oncology Department, Aix-Marseille University, Marseille, France., Gill S; Medical Oncology Department, Alfred Hospital, Melbourne, Australia., Griffin M; Clinical Oncology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK., Rogers L; Radiation Oncology Department, Gammawest Cancer Services, Salt Lake City, Utah, USA., Taal W; Neurology Department, Erasmus MC, Rotterdam, the Netherlands., Rudà R; Neuro-Oncology Department, University of Turin, Turin, Italy., Weller M; Neurology Department, University Hospital of Zurich, Zurich, Switzerland., McBain C; Clinical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK., van Linde ME; Medical Oncology Department, Amsterdam UMC, Amsterdam, the Netherlands., Sabedot TS; Neurosurgery Department, Henry Ford Health System, Detroit, Michigan, USA., Hoogstrate Y; Neurology Department, Erasmus MC, Rotterdam, the Netherlands., von Deimling A; Neuropathology Department, Ruprecht-Karls-University, Heidelberg, Germany.; Clinical Cooperation Unit Neuropathology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany., de Heer I; Neurology Department, Erasmus MC, Rotterdam, the Netherlands., van IJcken WFJ; Biomics Center, Erasmus MC, Rotterdam, the Netherlands., Brouwer RWW; Biomics Center, Erasmus MC, Rotterdam, the Netherlands., Aldape K; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Jenkins RB; Pathology Department, Mayo Clinic, Rochester, Minnesota, USA., Dubbink HJ; Pathology Department, Erasmus MC, Rotterdam, the Netherlands., Kros JM; Pathology Department, Erasmus MC, Rotterdam, the Netherlands., Wesseling P; Pathology Department, Amsterdam UMC, Amsterdam, the Netherlands.; Princess Máxima Center, Utrecht, the Netherlands., Cheung KJ; EORTC HQ, Brussels, Belgium., Golfinopoulos V; EORTC HQ, Brussels, Belgium., Baumert BG; Radiation Oncology Department, Maastricht UMC, Maastricht, the Netherlands.; Radiation Oncology Institute, Cantonal Hospital Graubünden, Chur, Switzerland., Gorlia T; EORTC HQ, Brussels, Belgium., Noushmehr H; Neurosurgery Department, Henry Ford Health System, Detroit, Michigan, USA., French PJ; Neurology Department, Erasmus MC, Rotterdam, the Netherlands.

Publikováno v: Neuro-oncology [Neuro Oncol] 2021 Sep 01; Vol. 23 (9), pp. 1547-1559.

Metabolic reprogramming associated with aggressiveness occurs in the G-CIMP-high molecular subtypes of IDH1mut lower grade gliomas.

Autor: Ruiz-Rodado V; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Malta TM; Henry Ford Health System, Detroit, Michigan, USA., Seki T; Radiation Biology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA., Lita A; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Dowdy T; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Celiku O; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Cavazos-Saldana A; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Li A; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Liu Y; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Han S; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Zhang W; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Song H; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Davis D; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Lee S; Developmental Therapeutics Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA., Trepel JB; Developmental Therapeutics Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA., Sabedot TS; Henry Ford Health System, Detroit, Michigan, USA., Munasinghe J; National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, USA., Yang C; Division of Neurosurgical Research, Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany., Herold-Mende C; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Gilbert MR; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA., Cherukuri MK; Radiation Biology Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA., Noushmehr H; Henry Ford Health System, Detroit, Michigan, USA., Larion M; Neuro-Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA.

Publikováno v: Neuro-oncology [Neuro Oncol] 2020 Apr 15; Vol. 22 (4), pp. 480-492.